Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV.

被引：0
|
作者：
Virik, K.
Skedgel, C.
Younis, T.
机构：
[1] QEII Hlth Sci Ctr, Halifax, NS, Canada
[2] Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6046
引用
收藏
页码：312S / 312S
页数：1
相关论文
共 50 条
  • [1] Potential budget impact of capecitabine versus 5-FU/LV as adjuvant chemotherapy for stage III (SIII) colon cancer in Canada and its provinces
    Virik, K.
    Skedgel, C.
    Younis, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer
    Ayvaci, Mehmet U. S.
    Shi, Jinghua
    Alagoz, Oguzhan
    Lubner, Sam J.
    [J]. MEDICAL DECISION MAKING, 2013, 33 (04) : 521 - 532
  • [3] Italian economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes'c colon cancer
    Di Costanzo, F.
    Sobrero, A.
    Twelves, C.
    Douillard, J.
    Giuliani, G.
    Patel, K.
    Garrison, L.
    Cassidy, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 63 - 63
  • [4] Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
    Bonin, Serena
    [J]. EBIOMEDICINE, 2015, 2 (08): : 780 - +
  • [5] The role of levamisole (LEV) in the adjuvant treatment of stage III colon cancer (CC): A randomized trial of LEV and 5-fluorouracil (5FU) versus 5FU alone on behalf of "Colon Adiuvante Marche".
    Catalano, V
    Cascinu, S
    Silva, RR
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Catalano, G
    Cellerino, R
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 52 - 52
  • [6] A role for levamisole (LEV) in the adjuvant treatment of stage III colon cancer: A randomized trial of 5-fluorouracil (5FU) and LEV vs 5FU alone
    Catalano, V
    Cascinu, S
    Latini, L
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Silva, RR
    Pieroni, V
    Giorgi, F
    Testa, I
    Sturba, F
    Ferretti, B
    Catalano, G
    Cellerino, R
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 66 - 66
  • [7] Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years.
    de Gramont, A
    Boni, C
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Bonetti, A
    Clingan, P
    Marceau-Suissa, J
    Lorenzato, C
    André, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 246S - 246S
  • [8] Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis
    Hickish, Tamas
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Bonetti, Andrea
    Clingan, Philip
    Figer, Arie
    Andre, Thierry
    de Gramont, Aimery
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [9] Economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes' C colon cancer in an Italian hospital setting
    Di Costanzo, F.
    Sobrero, A.
    Twelves, C.
    Cassidy, J.
    Douillard, J.-Y.
    Giuliani, G.
    Patel, K. K.
    Garrison, L. P.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 192 - 192
  • [10] Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU plus Ox)
    O'Connell, Michael
    Lee, Mark
    Lopatin, Margarita
    Yothers, Greg
    Clark-Langone, Kim
    Millward, Carl
    Paik, Soonmyung
    Sharif, Saima
    Shak, Steven
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345